198 related articles for article (PubMed ID: 34797617)
1. Medicare Coverage of Aducanumab - Implications for State Budgets.
Sachs RE; Bagley N
N Engl J Med; 2021 Nov; 385(22):2019-2021. PubMed ID: 34797617
[No Abstract] [Full Text] [Related]
2. Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform.
Robinson JC
N Engl J Med; 2021 Nov; 385(22):2017-2019. PubMed ID: 34797614
[No Abstract] [Full Text] [Related]
3. Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?
Schulman KA; Greicius MD; Richman B
JAMA; 2021 Aug; 326(5):383-384. PubMed ID: 34279572
[No Abstract] [Full Text] [Related]
4. Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.
Moghavem N; Henderson VW; Greicius MD
Ann Neurol; 2021 Sep; 90(3):331-333. PubMed ID: 34278596
[No Abstract] [Full Text] [Related]
5. The APTA electrical stimulation lawsuit and its aftermath. American Physical Therapy Association.
Kloth LC
Adv Wound Care; 1999; 12(9):472-5. PubMed ID: 10687560
[No Abstract] [Full Text] [Related]
6. State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.
Dale SB; Verdier JM
Issue Brief (Commonw Fund); 2003 Apr; (627):1-12. PubMed ID: 12685428
[No Abstract] [Full Text] [Related]
7. Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
Reiss JB
Food Drug Law J; 1997; 52(1):99-108. PubMed ID: 10346713
[No Abstract] [Full Text] [Related]
8. Perspectives. IGT ban, flexibility on tap for Medicaid, but what for Medicare?
Med Health; 2005 Mar; 59(6 Spec no.):1, 7-8. PubMed ID: 17066525
[No Abstract] [Full Text] [Related]
9. Medicare changes: fairer payments, delay in practice expenses.
Minn Med; 1997 Sep; 80(9):35. PubMed ID: 9322419
[No Abstract] [Full Text] [Related]
10. One pill, many prices: variation in prescription drug prices in selected government programs.
Gencarelli DM
Issue Brief George Wash Univ Natl Health Policy Forum; 2005 Aug; (807):1-20. PubMed ID: 16167399
[TBL] [Abstract][Full Text] [Related]
11. Medicare home health coverage.
Stein JA
Care Manag J; 2000; 2(3):178-89. PubMed ID: 11398574
[No Abstract] [Full Text] [Related]
12. How the ACA is reshaping medicine. Improvements in compensation, payer collaboration offset by provider shortages, incentive uncertainty.
Hertz BT
Med Econ; 2013 Feb; 90(4):30, 32, 39. PubMed ID: 23875281
[No Abstract] [Full Text] [Related]
13. Affordable prescription drugs--state and federal action.
Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: Medicare Part D. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-32. PubMed ID: 23297447
[No Abstract] [Full Text] [Related]
15. The value of neurosurgery.
Hadley MN
Neurosurgery; 2004 Apr; 54(4):777-82. PubMed ID: 15046643
[No Abstract] [Full Text] [Related]
16. Medicare program; supplementary medical insurance premium surcharge agreements. Final rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2002 Sep; 67(188):60993-7. PubMed ID: 12358040
[TBL] [Abstract][Full Text] [Related]
17. Medicare and Medicaid programs; civil money penalties for nursing homes. Final Rule.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2011 Mar; 76(53):15106-28. PubMed ID: 21434455
[TBL] [Abstract][Full Text] [Related]
18. AWP reimbursement scrutinized by several states.
Carroll J
Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
[No Abstract] [Full Text] [Related]
19. Covering and Reimbursing Telehealth Services.
Blackman K
NCSL Legisbrief; 2016 Jan; 24(4):1-2. PubMed ID: 27032126
[TBL] [Abstract][Full Text] [Related]
20. Limiting State Flexibility in Drug Pricing.
Bagley N; Sachs RE
N Engl J Med; 2018 Sep; 379(11):1002-1004. PubMed ID: 30207910
[No Abstract] [Full Text] [Related]
[Next] [New Search]
